Degarelix
- Generic Name
- Degarelix
- Brand Names
- Firmagon, Degarelix Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C82H103ClN18O16
- CAS Number
- 214766-78-6
- Unique Ingredient Identifier
- SX0XJI3A11
- Background
Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH) which ultimately causes testosterone s...
- Indication
Degaralix is used for the management of advanced prostate cancer.
- Associated Conditions
- Advanced Prostate Cancer
- Associated Therapies
- -
3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy
- Conditions
- Interventions
- First Posted Date
- 2012-12-18
- Last Posted Date
- 2021-11-19
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 124
- Registration Number
- NCT01751451
- Locations
- 🇺🇸
Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, United States
🇺🇸Memorial Sloan Kettering West Harrison, Harrison, New York, United States
🇺🇸NorthShore University Health System, Long Island City, New York, United States
Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation
- Conditions
- Interventions
- First Posted Date
- 2012-12-11
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 82
- Registration Number
- NCT01746849
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
One Month Degarelix/Comparator Treatment for Prostate Cancer in Chinese Population
- First Posted Date
- 2012-12-06
- Last Posted Date
- 2015-06-23
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 285
- Registration Number
- NCT01744366
- Locations
- 🇨🇳
Affiliated Southwest Hospital of 3rd Military Medical University of People's Liberation Army, Chongqing, Chongqing, China
🇨🇳2nd.Affiliated Hospital of Xi'an Jiaotong University College of Medicine, Xi'an, Shanxi, China
🇨🇳Cancer Institute & Hospital. Chinese Academy of Medical Sciences, Beijing, Beijing, China
Degarelix Acetate Before and During Radiation Therapy in Treating Patients With Prostate Cancer
- First Posted Date
- 2012-11-22
- Last Posted Date
- 2019-01-18
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 16
- Registration Number
- NCT01731912
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Degarelix in the Treatment of Endometriosis Recurrence
- Conditions
- Interventions
- First Posted Date
- 2012-10-24
- Last Posted Date
- 2024-03-06
- Target Recruit Count
- 360
- Registration Number
- NCT01712763
- Locations
- 🇮🇹
Cerm-Hungaria, Rome, Italy
🇧🇬Nadezda Women's Health Hospital, Sofia, Bulgaria
🇦🇱Albania Spitali Amerikan, Tirana, Albania
Treatment of Prostate Cancer With Firmagon®
- First Posted Date
- 2012-10-18
- Last Posted Date
- 2020-04-13
- Lead Sponsor
- United Clinic Management GmbH
- Target Recruit Count
- 100
- Registration Number
- NCT01710098
- Locations
- 🇩🇪
UCM GmbH, Planegg, Bavaria, Germany
Degarelix Neo-Adjuvant Radical Prostatectomy Trial
- Conditions
- Interventions
- First Posted Date
- 2012-08-28
- Last Posted Date
- 2015-12-22
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 35
- Registration Number
- NCT01674270
- Locations
- 🇨🇦
Vancouver General Hospital, Vancouver, British Columbia, Canada
🇨🇦University Health Network, Toronto, Ontario, Canada
Efficacy Study of Switching to a Lutenizing Hormone-releasing Hormone (LHRH) Antagonist From a LHRH Agonist to Treat Progressive Castrate Resistant Prostate Cancer (CRPC)
- First Posted Date
- 2012-06-28
- Last Posted Date
- 2012-06-28
- Lead Sponsor
- British Columbia Cancer Agency
- Target Recruit Count
- 40
- Registration Number
- NCT01630967
- Locations
- 🇨🇦
British Columbia Cancer Agency, Vancouver, British Columbia, Canada
A Phase II Study of Degarelix in the Management of Non-Metastatic Hormone-Refractory Prostate Cancer
- First Posted Date
- 2012-03-07
- Last Posted Date
- 2020-05-07
- Lead Sponsor
- Ottawa Hospital Research Institute
- Target Recruit Count
- 5
- Registration Number
- NCT01545882
- Locations
- 🇨🇦
Princess Margeret Hospital, Toronto, Ontario, Canada
🇨🇦London Regional Cancer Centre, London, Ontario, Canada
🇨🇦Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada
Firmagon (Degarelix) Intermittent Therapy
- First Posted Date
- 2012-01-19
- Last Posted Date
- 2019-09-23
- Lead Sponsor
- Canadian Urology Research Consortium
- Target Recruit Count
- 144
- Registration Number
- NCT01512472
- Locations
- 🇨🇦
Ultra-Med Research, Pointe Claire, Quebec, Canada
🇨🇦The Prostate Centre, Vancouver, British Columbia, Canada
🇨🇦Centre of Clinical Research, Halifax, Nova Scotia, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.